Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon-alpha-2a vs Low-dose Interferon-alpha-2a in Melanoma
NCT00204529Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2004
- Primary completion
- May 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in Malignant Melanoma (MM), sponsored by University Hospital Tübingen. Started Oct 2004; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00204529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204529.